OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Status: Recruiting
Location: See all (26) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients aged \>18 years at study index date AND

• A reported diagnosis code for amyloidosis OR

• A claim for ATTR-specific treatment OR

• A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR

Locations
United States
Minnesota
Research Site
COMPLETED
Eden Prairie
Other Locations
Canada
Research Site
RECRUITING
Calgary
China
Research Site
COMPLETED
Beijing
Research Site
COMPLETED
Changsha
Research Site
COMPLETED
Chengdu
Research Site
COMPLETED
Guangzhou
Research Site
COMPLETED
Wuhan
Denmark
Research Site
COMPLETED
Horsens
Germany
Research Site
COMPLETED
Berlin
Japan
Research Site
COMPLETED
Tokyo
Portugal
Research Site
RECRUITING
Lisbon
Research Site
NOT_YET_RECRUITING
Porto
Spain
Research Site
COMPLETED
A Coruña
Research Site
COMPLETED
Barcelona
Research Site
COMPLETED
Bilbao
Research Site
COMPLETED
El Palmar
Research Site
COMPLETED
Huelva
Research Site
COMPLETED
Las Palmas De Gran Canaria
Research Site
COMPLETED
Madrid
Research Site
COMPLETED
Majadahonda
Research Site
COMPLETED
Palma De Mallorca
Research Site
COMPLETED
Salamanca
Research Site
COMPLETED
Valencia
Sweden
Research Site
COMPLETED
Södertälje
Research Site
COMPLETED
Umeå
United Kingdom
Research Site
COMPLETED
London
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2023-08-21
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 55000
Treatments
ATTR cardiomyopathy
Patients with Transthyretin Amyloidosis Cardiomyopathy
ATTR polyneuropathy
Patients with Transthyretin Amyloidosis Neuropathy
ATTR unknown
Patients with ATTR unknown genotype
ATTR with mixed phenotype
Patients with ATTR mixed phenotype
ATTR wild type
Patients with Transthyretin Amyloidosis wild type
ATTR hereditary
Patients with Transthyretin Hereditary
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov